Arcturus Therapeutics Holdings Inc.

NasdaqGM:ARCT 株式レポート

時価総額:US$669.6m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Arcturus Therapeutics Holdings 過去の業績

過去 基準チェック /06

Arcturus Therapeutics Holdingsは5.1%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで15.5%毎年増加している。売上は成長しており、年平均60.6%の割合である。

主要情報

6.8%

収益成長率

12.9%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率56.9%
株主資本利益率-27.8%
ネット・マージン-43.9%
前回の決算情報30 Jun 2024

最近の業績更新

Recent updates

Improved Revenues Required Before Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock's 28% Jump Looks Justified

Oct 04
Improved Revenues Required Before Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock's 28% Jump Looks Justified

Here's Why We're Not Too Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Situation

Sep 06
Here's Why We're Not Too Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Situation

High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine

Aug 09

Arcturus: A Hidden Gem In The Biotech Sector

Jun 08

Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Share Price Boosted 45% But Its Business Prospects Need A Lift Too

May 29
Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Share Price Boosted 45% But Its Business Prospects Need A Lift Too

Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis

Apr 23

Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business

Apr 09
Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business

Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking

Feb 06
Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking

Arcturus: H1 2024 Rare Disease Drug Data On Deck

Jan 31

Does Arcturus Therapeutics Holdings (NASDAQ:ARCT) Have A Healthy Balance Sheet?

Jan 11
Does Arcturus Therapeutics Holdings (NASDAQ:ARCT) Have A Healthy Balance Sheet?

Are Investors Undervaluing Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) By 46%?

Dec 14
Are Investors Undervaluing Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) By 46%?

Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Shares Lagging The Industry But So Is The Business

Sep 14
Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Shares Lagging The Industry But So Is The Business

Some Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Made A Major Cut To Next Year's Estimates

Aug 08
Some Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Made A Major Cut To Next Year's Estimates

Calculating The Fair Value Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Jul 19
Calculating The Fair Value Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Broker Revenue Forecasts For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Are Surging Higher

May 18
Broker Revenue Forecasts For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Are Surging Higher

Arcturus Therapeutics Holdings (NASDAQ:ARCT) Has A Rock Solid Balance Sheet

May 02
Arcturus Therapeutics Holdings (NASDAQ:ARCT) Has A Rock Solid Balance Sheet

Here's Why Arcturus Therapeutics Holdings (NASDAQ:ARCT) Can Manage Its Debt Despite Losing Money

Dec 28
Here's Why Arcturus Therapeutics Holdings (NASDAQ:ARCT) Can Manage Its Debt Despite Losing Money

Arcturus Therapeutics Holdings (NASDAQ:ARCT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Sep 23
Arcturus Therapeutics Holdings (NASDAQ:ARCT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Arcturus rises 6% on $63.2M award from U.S. government for mRNA vaccine

Aug 31

Analysts Just Published A Bright New Outlook For Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT)

Aug 15
Analysts Just Published A Bright New Outlook For Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT)

Arcturus Therapeutics downgraded to underperform at Raymond James on program setbacks

Aug 10

Arcturus: Potential Based On Rare Disease Therapy ARCT-810

Jun 07

These Analysts Think Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Sales Are Under Threat

May 11
These Analysts Think Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Sales Are Under Threat

収支内訳

Arcturus Therapeutics Holdings の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGM:ARCT 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Jun 24164-72536
31 Mar 24125-107540
31 Dec 23167-30530
30 Sep 23296995297
30 Jun 23264805197
31 Mar 23281111490
31 Dec 222069460
30 Sep 2252-147470
30 Jun 2241-165450
31 Mar 2215-198440
31 Dec 2112-204410
30 Sep 219-196420
30 Jun 219-163360
31 Mar 219-119310
31 Dec 2010-72250
30 Sep 2010-52180
30 Jun 2011-38170
31 Mar 2019-29160
31 Dec 1921-26140
30 Sep 1925-1670
30 Jun 1926-1370
31 Mar 1918-22120
31 Dec 1816-22130
30 Sep 1810-26210
30 Jun 1810-25190
31 Mar 1812-16120
31 Dec 1713-1180
31 Dec 1620-230
31 Dec 156-230

質の高い収益: ARCTは現在利益が出ていません。

利益率の向上: ARCTは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: ARCTは利益を出していないが、過去 5 年間で年間5.1%の割合で損失を削減してきた。

成長の加速: ARCTの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: ARCTは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。


株主資本利益率

高いROE: ARCTは現在利益が出ていないため、自己資本利益率 ( -40.65% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘